AG Mednet, Inc.’s Post

💡 Did you know.. Last fall, Lantern Pharma Inc. (Nasdaq: LTRN) received an #OrphanDrugDesignation from the #FDA for LP-284, which treats a rare and aggressive form of non-Hodgkin’s lymphoma that lacks a standard treatment. LP-284 didn’t exist when Lantern went public in 2020, and less than three years later, with just $3 million in development costs, it is currently in Phase 1 #ClinicalTrial with initial patients dosed. Check out this new article on D Magazine by Will Maddox - "How Lantern Pharma’s AI Is Changing the Game" to learn more about LP-284 and how Lantern Pharma Inc. (Nasdaq: LTRN) is transforming both cost and timeline of drug development leveraging Lantern's proprietary #AI and #ML platform RADR. Check out the full article here! https://lnkd.in/e6qUB4JH #DrugDiscovery #DrugDevelopment #Oncology #CEO #AIinCancerResearch

𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 (𝗧𝗥𝗧) are an emerging cancer treatment modality. Our latest blog explores how modeling and simulation technology can help with TRT dose optimization. https://ow.ly/5C4p50QZ5OB #CancerResearch #TargetedRadiationTherapy #CancerTreatment #Oncology #ClinicalTrials #FDAguidelines #EMAguidelines #ProjectOptimus #ModelingSimulation #PKdata #DoseSelection #ClinicalPharmacology

Congratulations to Insilico Medicine for receiving IND Approval for their theraputic (designed by AI) to treat MTAP deleted cancers! 🎉 🎊 https://lnkd.in/dupP_M_H #ai #drugdevelopment ##drugdiscovery #innovation #FDA #IND #vc #biopharma #biology #molecularbiology #cancer #cancerresearch #oncology #oncologyresearch

How can we leverage preclinical findings effectively to guide clinical dosage strategies for cancer combinations? Experts at the groundbreaking 2nd ASCO-FDA workshop addressed this crucial question. Our recent blog post explores the application of their cutting-edge guidance on deciphering preclinical data. Don't miss out on these valuable insights that can shape your research. Read more here: https://ow.ly/7v5Q50QbwCI #DosageOptimization #FDA #CancerResearch #DrugApproval #ClinicalPharmacology 

Cancer remains a formidable foe, its complexity leaving traditional drug discovery methods lagging behind. But a beacon of hope shines bright: artificial intelligence (AI). This transformative technology is revolutionizing cancer research, from uncovering intricate disease mechanisms to guiding personalized treatment strategies. This article delves into the exciting world of AI in cancer research, exploring: 👉 Breaking the mold: How AI is accelerating the identification of novel drug targets previously hidden within vast datasets. 👉 Precision redefined: Unveiling individual patient profiles with AI-powered biomarker discovery, leading to personalized treatment plans for maximum efficacy and minimized side effects. 👉 Repurposing heroes: AI-driven drug repurposing breathes new life into existing medications, accelerating the development of effective therapies. 👉 Predicting tomorrow's challenges: Battling drug resistance with AI algorithms that adapt treatment strategies in real-time, staying one step ahead of cancer's evolution. 👉 Optimizing every step: From radiotherapy planning to clinical decision support, AI empowers healthcare professionals with unparalleled insights, optimizing the entire treatment journey. Ready to join the fight against cancer with the power of AI? The Medicinal Chemistry Strategy Meeting in Princeton and San Diego brings together leading experts to explore the cutting edge of AI-driven cancer research. Join us and discover: ✔ Groundbreaking research: Hear from renowned scientists presenting the latest advancements in AI-powered drug discovery and personalized medicine. ✔ Collaboration opportunities: Network with fellow researchers, clinicians, and industry leaders to foster partnerships and accelerate progress. ✔ Actionable insights: Gain practical knowledge and strategies to integrate AI into your own research and clinical practice. Don't miss this chance to be part of the revolution! Register for the Medicinal Chemistry Strategy Meeting today! Register for Princeton - https://lnkd.in/grQ3cU7m Register for San Diego- https://lnkd.in/g6-cEjyr #CancerResearch #AIinHealthcare #PrecisionMedicine #FutureofCancerCare #DrugDiscovery #PersonalizedTreatment #AIforGood #HealthTech #TargetIdentification #BiomarkerDiscovery #DrugRepurposing #DrugResistance #RadiotherapyPlanning #ClinicalDecisionSupport #CancerGenomics #MachineLearning #DeepLearning #Oncologists #Researchers #PharmaceuticalIndustry #Patients #PatientAdvocates #HealthcareProfessionals #MedicinalChemistry #StrategyMeeting #Princeton #SanDiego #Network #Collaboration #ActionableInsights

Unlocking the potential of synthetic lethality in cancer treatment - are we on the brink of a breakthrough? 🧬   👇Dive into this insightful article published in the Nature Research Custom Media Journal's Spotlight on Switzerland, that offers a taste of our learnings from the past decade. Discover how we're leveraging artificial intelligence to identify novel drug combinations and aiming to address critical needs in oncology like penetrance into the blood-brain barrier. Join us as we strive to outpace cancer cell resistance and deliver treatments that could change the lives of cancer patients. ✨ #CancerTreatment #MedicalInnovation #Oncology #PrecisionMedicine

Super exciting to see Kyverna Therapeutics add to the list of biotech's filing for IPO in 2024, with a larger-than-expected raise of $319 million. There are over 530 cell therapies in development for immune-mediated diseases and 354 of them are investigating system lupus erythematosus. That's quite the competition for Kyverna and other oncology cell therapy specialists pivoting to autoimmune conditions. Aside from this, I think it represents positive investor sentiment for the biotech space. #lupus #autoimmune #inflammation #celltherapy https://lnkd.in/etJj4Prs

Multiple Sclerosis News Today reports on a new CAR T-cell therapy intended to improve lives of patients with MS. On our Insights page, discover how Judi for Eligibility and Judi for Adjudication supports a prominent biotech on a pivotal Phase 2 CAR T-cell #oncology #clinicaltrial. Judi.io

Although there have been strides in traditional oncology drug discovery and development, the intricate nature and diverse characteristics of cancer have impeded the development of efficacious treatments. Nevertheless, the advent of AI has provided new avenues for addressing these challenges. https://lnkd.in/eM3CC462 #oncotherapeutics #machinelearning #artificialintelligence #drugdiscovery #drugdevelopment #targetidentification #targetvalidation #proteomics #phenotypicscreening #biomarkers #drugrepurposing #deeplearning